Literature DB >> 11748958

Plasmodium falciparum cytoadherence to human placenta: evaluation of hyaluronic acid and chondroitin 4-sulfate for binding of infected erythrocytes.

M Valiyaveettil1, R N Achur, A Alkhalil, C F Ockenhouse, D C Gowda.   

Abstract

Chondroitin 4-sulfate (C4S) is known to mediate the adherence of Plasmodium falciparum infected red blood cells (IRBCs) to human placenta. Recently, hyaluronic acid (HA) has also been reported to bind IRBCs, and HA has been suggested as an additional receptor for the sequestration of IRBCs in the placenta. In this study, we assessed the adherence of 3D7 parasite strain, which has been reported to bind both C4S and HA, using highly purified clinical grade rooster comb HA, Streptococcus HA, several preparations of human umbilical cord HA (hucHA), and bovine vitreous humor HA (bvhHA). While all hucHA preparations and bvhHA bound with moderate to high density to IRBCs, the rooster comb and bacterial HAs did not bind IRBCs. IRBCs binding to the hucHA and bvhHA could be abolished by pretreatment with testicular hyaluronidase but not with Streptomyces hyalurolyticus hyaluronidase, suggesting that IRBC binding to hucHA and bvhHA was due to chondroitin sulfate (CS) contaminants in HAs. Compositional analysis confirmed the presence of CS in both hucHA and bvhHA. The CSs present in these commercial hucHA and bvhHA samples were isolated, characterized, and studied for their ability to bind IRBCs. The data suggested that IRBC adherence to hucHA and bvhHA was mediated by the CS present in these samples. However, our data did not exclude the possibility of a minor population of distinct parasite subtype adhering to HA and further studies using pure HA conjugated to proteins or lipids and placental parasite isolates should clarify whether HA is an in vivo receptor for IRBC adherence. Copyright 2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748958     DOI: 10.1006/expr.2001.4642

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  6 in total

1.  Adhesion specificities of Plasmodium falciparum-infected erythrocytes involved in the pathogenesis of pregnancy-associated malaria.

Authors:  Lars Hviid
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

2.  Chondroitin sulfate proteoglycan but not hyaluronic acid is the receptor for the adherence of Plasmodium falciparum-infected erythrocytes in human placenta, and infected red blood cell adherence up-regulates the receptor expression.

Authors:  Arivalagan Muthusamy; Rajeshwara N Achur; Manojkumar Valiyaveettil; John J Botti; Diane W Taylor; Rose F Leke; D Channe Gowda
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

3.  An affinity chromatography and glycoproteomics workflow to profile the chondroitin sulfate proteoglycans that interact with malarial VAR2CSA in the placenta and in cancer.

Authors:  Alejandro Gómez Toledo; Jessica Pihl; Charlotte B Spliid; Andrea Persson; Jonas Nilsson; Marina Ayres Pereira; Tobias Gustavsson; Swati Choudhary; Htoo Zarni Oo; Peter C Black; Mads Daugaard; Jeffrey D Esko; Göran Larson; Ali Salanti; Thomas Mandel Clausen
Journal:  Glycobiology       Date:  2020-12-09       Impact factor: 4.313

4.  Utilization of 18s ribosomal RNA LAMP for detecting Plasmodium falciparum in microscopy and rapid diagnostic test negative patients.

Authors:  Enoch Aninagyei; Adjoa Agyemang Boakye; Clement Okraku Tettey; Kofi Adjei Ntiri; Samuel Ohene Ofori; Comfort Dede Tetteh; Thelma Teley Aphour; Tanko Rufai
Journal:  PLoS One       Date:  2022-10-06       Impact factor: 3.752

5.  Molecular aspects of Plasmodium falciparum Infection during pregnancy.

Authors:  Nicaise Tuikue Ndam; Philippe Deloron
Journal:  J Biomed Biotechnol       Date:  2007

6.  Disruption of var2csa gene impairs placental malaria associated adhesion phenotype.

Authors:  Nicola K Viebig; Emily Levin; Sébastien Dechavanne; Stephen J Rogerson; Jürg Gysin; Joseph D Smith; Artur Scherf; Benoit Gamain
Journal:  PLoS One       Date:  2007-09-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.